Anaptysbio Inc.

Address: 10770 Wateridge Circle Suite 210

Sponsor Overview

assignment

Specializations

Inflammatory Skin Disease

Clinical research in atopic dermatitis focuses on immune-mediated skin inflammation and persistent pruritus, with attention to disease control in moderate to severe cases.

Atopic dermatitis
Immune dysregulation
Chronic pruritic dermatitis

The sponsor’s portfolio places substantial emphasis on dermatologic inflammation and conditions driven by aberrant immune signaling.

Gastrointestinal Immune Disorders

Research activity extends to ulcerative colitis, celiac disease, and eosinophilic esophagitis, reflecting a focus on inflammatory and immune-based disorders of the digestive tract.

Ulcerative colitis
Celiac disease
Eosinophilic esophagitis

These programs address mucosal inflammation, food-related immune activation, and eosinophil-associated disease in the gastrointestinal tract.

Rheumatologic Inflammation

Clinical studies in moderate to severe rheumatoid arthritis center on joint inflammation, systemic immune activation, and the burden of chronic autoimmune disease.

Rheumatoid arthritis
Autoimmune joint disease
Systemic inflammation

This area reflects interest in therapies aimed at controlling inflammatory pathways involved in synovial disease and progressive joint damage.

Targeted Immunology Programs

The sponsor also funds research into investigational immunology programs, including work associated with ANB032, rosnilimab, and ANB033, indicating a broader interest in pathway-directed immune modulation.

Immune pathway modulation
Inflammatory disease biology
Translational immunology

These studies connect dermatology, gastroenterology, and rheumatology through shared mechanisms of immune-mediated inflammation.

Trial Name	Country	Status
Efficacy and Safety Evaluation of Rosnilimab in Moderate to Severe Rheumatoid Arthritis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study	Belgium Estonia France Germany Hungary Italy Poland Slovakia Spain	Not Recruiting
Efficacy and Safety of ANB032 with Hydrocortisone/Alclometasone Dipropionate in Patients with Moderate to Severe Atopic Dermatitis: Randomized Phase 2 Study	Czechia Poland	Not Yet Recruiting
Evaluation of ANB032 Efficacy and Safety in Moderate to Severe Atopic Dermatitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial	Czechia Poland	Not Recruiting
Evaluation of Rosnilimab Efficacy and Safety in Moderate to Severe Ulcerative Colitis: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study	Austria Bulgaria Croatia France Germany Italy Poland Romania Spain The Netherlands	Not Recruiting